Trabectedin
Back to searchMolecule Structure
Scientific Name
Trabectedin
Description of the Drug
Trabectedin is an alkylating agent approved for the treatment of unresectable or metastatic soft tissue sarcoma (liposarcoma or leiomyosarcoma).
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB05109
http://www.drugbank.ca/drugs/DB05109
Brand Name(s)
Yondelis
Company Owner(s)
Janssen Products Lp
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
DNA | NUCLEIC-ACID | INHIBITOR | CHEMBL2311221 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL12119916 | |
PharmGKB | PA165958349 | |
Human Metabolome Database | HMDB0015609 | |
DrugBank | DB05109 | |
PubChem: Thomson Pharma | 14938004 | 16067487 |
PubChem | 108150 | |
NMRShiftDB | 70082190 | |
Nikkaji | J1.013.169C | |
PDBe | ECT | |
EPA CompTox Dashboard | DTXSID2046880 | |
DrugCentral | 4633 | |
Metabolights | MTBLC84050 | |
ChemicalBook | CB31364731 | |
Guide to Pharmacology | 2774 | |
rxnorm | TRABECTEDIN | |
PubChem: Drugs of the Future | 12014180 | |
ChEBI | 84050 | |
ZINC | ZINC000150338708 |